Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data
Stock Down By 55%
Executive Summary
The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.
You may also be interested in...
Altimmune Regains Some Momentum
Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.